US Medicare patients have now been given access to cannabidiol (CBD) products through a landmark federal pilot scheme, helping boost cannabis stocks.
While many investors have taken CBD being included inside a formal care setting for the first time as a marker of medical legitimisation, for now, the scheme remains strictly limited.
In a memo published by the US Food and Drug Administration (FDA) last week, the administration confirmed that it will not enforce certain rules that would normally restrict CBD products, as long as they are used within these programmes and meet specific conditions.
The policy works alongside a Centers for Medicare & Medicaid Services (CMS) initiative that allows healthcare providers in selected programmes, including ACO REACH and the Enhancing Oncology Model, to give patients up to $500 worth of CBD products per year. These products can be provided directly to patients during care, rather than requiring them to purchase CBD themselves.
This has already seen a number of producers vying to ensure their products are included in the limited schemes, with further expansions of the scheme set to be rolled out in the coming months.
boc_stock symbol=”MSOS”Limited, but a landmark
In its memo, Hemp-Derived Cannabidiol Products in Medical Research Models, the FDA states it does not intend to enforce sections 502(f)(1) and 505 of the Federal Food, Drug, and Cosmetic Act for qualifying hemp-derived CBD products when furnished to Medicare beneficiaries under Title XVIII programmes.
The policy applies to orally administered products provided under physician direction as part of a broader course of care.
It follows Executive Order 14370, signed in December 2025, which directed federal agencies to expand research and explore access pathways for cannabis-derived products.
Importantly, Medicare is not covering the cost. Providers must pay for the products, and patients are not expected to submit claims. In practice, this means some patients may receive CBD at no cost, but it is not part of standard Medicare coverage.
Furthermore, only certain types of products are allowed. They must be hemp-derived, meet federal THC limits, and cannot be inhaled. The rules are designed to keep the programme tightly controlled while allowing researchers and providers to test how CBD might be used in healthcare.
The move comes as US regulators continue to work on broader rules for CBD. In March, the FDA submitted a draft policy on CBD regulation to the White House for review by the Office of Information and Regulatory Affairs, but full details have not yet been released.
At the same time, new federal rules on hemp are due to take effect in November 2026, tightening limits on THC. These changes could reduce the number of CBD products that qualify under federal law, which may affect what can be used in the programme.
READ MORE…
Commercial Momentum Builds, But Legal Risks Emerge
The policy shift has already triggered a notable market response. Cannabis equities recorded their strongest weekly performance in months as investors reacted to signs that CBD is beginning to enter regulated healthcare channels.
The AdvisorShares Pure US Cannabis ETF, which tracks leading US cannabis companies, rose sharply following the announcements, reflecting renewed optimism around federal reform.
Meanwhile, early signs of commercial positioning are emerging. Cornbread Hemp said it has secured an exclusive supply agreement with Alliant Purchasing, a group purchasing organisation whose network includes tens of thousands of provider locations participating in CMS-linked models.
The company said the arrangement would allow its products to be distributed through established healthcare procurement channels, subject to approval by participating organisations.
Despite this positive movement, the rollout is already facing legal scrutiny. Smart Approaches to Marijuana and a coalition of organisations have filed a lawsuit challenging the CMS initiative, arguing that it exceeds the agency’s authority and was implemented without proper rulemaking procedures.
A federal judge has denied an initial request to halt the programme but is scheduled to hear arguments on a preliminary injunction later this month.
With this in mind, the long-term outlook for the programme remains uncertain. Its success will depend not only on uptake within CMS models, but also on how federal regulators resolve broader questions around CBD policy.
With new hemp rules due to take effect in November 2026, tightening THC limits and potentially narrowing the range of eligible products, the regulatory environment could shift significantly within months. At the same time, the US Food and Drug Administration has yet to publish full guidance on how CBD products will be regulated more broadly, leaving key compliance questions unresolved.
